Iindaba

Kwisiqingatha sokuqala se-2022, ukuthunyelwa ngaphandle kweemveliso zempilo ezifana namayeza aseKorea, izixhobo zonyango kunye nezithambiso zifikelele kwirekhodi eliphezulu.Iiarhente zokuxilonga i-COVID-19 kunye nezitofu zokugonya zongeza ukuthunyelwa ngaphandle.
Ngokutsho kweZiko loPhuhliso loShishino lwezeMpilo lwaseKorea (KHIDI), ukuthengiswa kwamanye amazwe kwi-13.35 yezigidigidi kwisiqingatha sokuqala salo nyaka.Elo nani linyuke nge-8.5% ukusuka kwi-12.3 yeebhiliyoni zeedola kwikota yonyaka ophelileyo kwaye yayisesona siphumo siphezulu sesiqingatha sonyaka.Irekhode ngaphezulu kwe-13.15 yeebhiliyoni zeedola kwisiqingatha sesibini sika-2021.
Ngoshishino, ukuthengiswa kwamayeza athunyelwa ngaphandle kwe-US $ 4.35 yebhiliyoni, ukunyuka kwe-45.0% ukusuka kwi-US $ 3.0 yezigidigidi ngexesha elifanayo ngo-2021. Ukuthunyelwa ngaphandle kwezixhobo zonyango kuye kwafikelela kwi-USD 4.93 yezigidigidi, ukuya kwi-5.2% ngonyaka.Ngenxa yokuvalelwa yedwa e-China, ukuthunyelwa kwezithambiso kumazwe angaphandle kwehle nge-11.9% ukuya kwi-4.06 yeebhiliyoni zeedola.
Ukukhula kokuthumela amayeza kumazwe angaphandle kwaqhutywa ngamayeza ebhayoloji kunye nezitofu zokugonya.Ukuthunyelwa ngaphandle kwe-biopharmaceuticals kufikelele kwi-1.68 yeebhiliyoni zeedola, ngelixa ukuthunyelwa kwamanye amazwe kwamayeza okugonya kuye kwafikelela kwi-780 yezigidi zeedola.Zombini zenza i-56.4% yazo zonke iimveliso ezithunyelwa ngaphandle.Ngokukodwa, ukuthunyelwa kwamanye amazwe kwamayeza okugonya kunyuke nge-490.8% unyaka nonyaka ngenxa yokwanda kokuthunyelwa kwamayeza okugonya okuchasene ne-COVID-19 avelisiweyo phantsi kokwenziwa kwekhontrakthi.
Kwinkalo yezixhobo zonyango, i-reagents yokuxilonga i-akhawunti yesabelo esikhulu kunazo zonke, ifikelela kwi-2.48 yeebhiliyoni zeedola, i-2.8% ukusuka kwixesha elifanayo kwi-2021. Ukongeza, ukuthunyelwa kwezixhobo zokucinga ze-ultrasound (i-390 yezigidi zeedola), ukufakelwa (i-340 yezigidi zeedola) kunye ne-X- izixhobo ray (izigidi ezingama-330 zeedola) zaqhubeka zikhula, ikakhulu e-US naseTshayina.